Current research has shown that TNBC or HER2+ breast cancer patients with cT1-2, cN0 status, and a pathologic complete response in the breast (ypT0) have very low rates (< 2%) of residual axillary disease after NST (ypN+).27, 28 Thus, these patients should be considered for risk-adaptive breast cancer surgery in future trials. This evidence concerns the gene ERBB2 and breast cancer.